Comment on page

Immunotherapy

Immunotherapy
Immunotherapy
Immunotherapy
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
N Engl J Med 2017; 377:2500-2501December 21, 2017DOI: 10.1056/NEJMc1713444
​http://www.nejm.org/doi/full/10.1056/NEJMc1713444?query=TOC​
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
N Engl J Med 2017; 377:2500-2501December 21, 2017DOI: 10.1056/NEJMc1713444
​http://www.nejm.org/doi/full/10.1056/NEJMc1713444?query=TOC​
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
N Engl J Med 2017; 377:2500-2501December 21, 2017DOI: 10.1056/NEJMc1713444
​http://www.nejm.org/doi/full/10.1056/NEJMc1713444?query=TOC​
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
N Engl J Med 2017; 377:2500-2501December 21, 2017DOI: 10.1056/NEJMc1713444
​http://www.nejm.org/doi/full/10.1056/NEJMc1713444?query=TOC​
Immunotherapy
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
N Engl J Med 2017; 377:2500-2501December 21, 2017DOI: 10.1056/NEJMc1713444
​http://www.nejm.org/doi/full/10.1056/NEJMc1713444?query=TOC​

Treatment and Pathology - Previous

Therapy related changes

Next - Treatment and Pathology

Prognostic, Predictive and Therapeutic Factors

Last modified 6mo ago